Varun Goel

Varun Goel

Auto-generated profile, based on publicly available information

Varun Goel

No affiliation

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2026 in Advances in Geriatric Medicine and Research
Verified
Journal Article
Open access
PDF file
NJNikhil Jaganathan
Nikhil Jaganathan
VGVarun Goel
Varun Goel
XLXiaoyue Liu
Xiaoyue Liu
WenZhan SongWenZhan Song
WenZhan Song
YKYounghoon Kwon
Younghoon Kwon
WHWilliam Healy
William Healy
With an aging population and greater prevalence of metabolic disorders, obstructive sleep apnea (OSA) is increasingly observed in older patients. OSA in older adults often occurs in the setting of various comorbidities, such as cognitive, cardiac, and metabolic dysfunction, placing these patients at greater risk. Continuous positive airway pressure (CPAP) is the first-line treatment for OSA in most patients, but adherence with CPAP decreases with increasing age. Current literature on considerations and efficacy of treatment modalities for OSA in older patients is limited. This narrative review summarizes current evidence on CPAP and non-CPAP therapies of OSA in older adults with particular attention to age-specific differences in clinical presentation, diagnostic challenges, and implications for quality of life. Relevant guidelines, clinical studies, and systematic reviews selected from the PubMed and Cochrane databases through April 2026 were summarized and categorized based on type of therapy. Some non-CPAP alternatives appear promising or effective in selected adults for improving metrics of sleep, quality of life, and mitigating comorbidities, but for geriatric-specific comparative evidence remains limited, indirect, observational, or derived from adults substantially younger than the target population. Lifestyle modifications, positional therapy, and oral appliances may yield benefits in older patients comparable to those seen in their younger counterparts, but age-stratified studies are limited. While pharmacotherapy is an area of emerging study, GLP-1 RAs show significant early potential with multifaceted benefits, although supporting studies have been primarily conducted in middle-aged adults. Hypoglossal nerve stimulation has emerged as a prominent OSA treatment alternative with improved adherence compared to CPAP in in small elderly-specific studies. OSA management in older patients is highly nuanced with multifactorial consideration of polypharmacy, comorbidities, and patient preferences to optimize patient outcomes. Larger-scale, prospective studies specific to older patients are warranted to assess treatment efficacy, adherence, and adverse effects in this population.

4 February 2025
Verified
Preprint
Open access
NJNikhil Jaganathan
Nikhil Jaganathan
VGVarun Goel
Varun Goel
RSRobert Sorrentino
Robert Sorrentino
DGDominic Gallo
Dominic Gallo
MDMallikarjuna R. Devarapalli
Mallikarjuna R. Devarapalli
Implantable cardioverter-defibrillators are medical devices designed to prevent sudden cardiac death caused by life-threatening ventricular arrhythmias. The purpose of this review is to investigate the most novel approach via an extravascular lead by exploring preliminary data that had been published in the PubMed, Cochrane, and ScienceDirect databases as of October 2024. An Oxford Level of Evidence was assigned to each paper; papers rated Level 4 or higher were included. Of the 727 initial records identified, 25 were included in the final analysis: 11 articles, and 14 abstracts. This data includes analysis of multiple-center studies of efficacy, safety, and complications of such devices and therapeutic use. This review discusses the expectations from clinical applications of extravascular implantable cardioverter-defibrillators and how certain limitations may be addressed.

23 January 2025
Verified
Preprint
Open access
NJNikhil Jaganathan
Nikhil Jaganathan
VGVarun Goel
Varun Goel
RSRobert Sorrentino
Robert Sorrentino
DGDominic Gallo
Dominic Gallo
MDMallikarjuna R. Devarapalli
Mallikarjuna R. Devarapalli
Implantable cardioverter-defibrillators are medical devices designed to prevent sudden cardiac death caused by life-threatening ventricular arrhythmias. The purpose of this review is to investigate the most novel approach via an extravascular lead by exploring preliminary data that had been published in the PubMed, Cochrane, and ScienceDirect databases as of October 2024. An Oxford Level of Evidence was assigned to each paper; papers rated Level 4 or higher were included. Of the 727 initial records identified, 25 were included in the final analysis: 11 articles, and 14 abstracts. This data includes analysis of multiple-center studies of efficacy, safety, and complications of such devices and therapeutic use. This review discusses the expectations from clinical applications of extravascular implantable cardioverter-defibrillators and how certain limitations may be addressed.